NCT07066397View on ClinicalTrials.gov

A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

April 1, 2041

Conditions
Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

ARM011

ARM011 is an autologous, CD19 targeted CAR T-cell product developed on fast-in-time (FIT) platform-a non-viral, 2-day rapid manufacturing process

DRUG

Fludarabine

Administered prior to infusion of ARM011

DRUG

Cyclophosphamide

Administered prior to infusion of ARM011

Trial Locations (1)

100229

RECRUITING

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

TriArm Therapeutics (Taiwan) Limited

INDUSTRY